Quick Comparison
| Mazdutide | Tirzepatide | |
|---|---|---|
| Half-Life | 144-192 hours (6-8 days) | 120 hours (5 days) |
| Typical Dosage | Approved (China): 6-9 mg subcutaneous once weekly. Dose escalation over initial weeks starting at lower doses. Clinical trial doses ranged from 3-9 mg subcutaneous once weekly. | Weight management (Zepbound): 2.5 mg subcutaneous once weekly for 4 weeks, increasing by 2.5 mg every 4 weeks to maintenance dose of 5-15 mg once weekly. Diabetes (Mounjaro): same escalation schedule, maintenance 5-15 mg subcutaneous once weekly. |
| Administration | Subcutaneous injection (weekly) | Subcutaneous injection (weekly) |
| Research Papers | 27 papers | 30 papers |
| Categories |
Mechanism of Action
Mazdutide
Mazdutide is a dual-receptor agonist that activates both GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure. The GLP-1 component functions similarly to other GLP-1 agonists — binding to receptors in the hypothalamus to reduce hunger, stimulating glucose-dependent insulin secretion from pancreatic beta cells, and slowing gastric motility to prolong post-meal satiety.
The glucagon receptor component distinguishes mazdutide from pure GLP-1 agonists. Glucagon binding in the liver activates adenylyl cyclase, increasing cAMP and activating protein kinase A, which phosphorylates key enzymes in fatty acid oxidation and ketogenesis. This drives the liver to burn stored fat as fuel rather than accumulate it — a mechanism with direct therapeutic relevance for patients with metabolic-associated fatty liver disease (MAFLD). In adipose tissue, glucagon signaling promotes lipolysis and may activate thermogenic programs in brown and beige fat cells.
The engineering challenge in dual GLP-1/glucagon agonists is balancing the hyperglycemic effect of glucagon against the glucose-lowering effects of GLP-1. Mazdutide achieves this by tuning the relative receptor affinities so that GLP-1-mediated insulin secretion offsets glucagon-driven glucose production, resulting in net glycemic improvement alongside enhanced fat oxidation and energy expenditure.
Tirzepatide
Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone.
The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus.
At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.
Risks & Safety
Mazdutide
Common
nausea, diarrhea, vomiting, reduced appetite, injection site reactions.
Serious
elevated liver enzymes, inflammation of the pancreas, gallstones.
Rare
thyroid concerns (seen with similar drugs in animals), severe liver damage.
Tirzepatide
Common
nausea (25-35%), diarrhea, constipation, vomiting, reduced appetite, stomach pain, redness at injection site.
Serious
inflammation of the pancreas (pancreatitis), gallstones, very slow stomach emptying (gastroparesis), low blood sugar if combined with other diabetes medications.
Rare
thyroid tumours seen in animal studies, severe allergic reactions, kidney problems.
Full Profiles
Mazdutide →
A weight loss injection that suppresses appetite while also boosting your metabolism and helping your liver burn fat. Approved in China for obesity in 2024, with up to 14% body weight loss in trials. It targets two hormones — GLP-1 (which reduces hunger) and glucagon (which increases calorie burning and liver fat breakdown). Particularly promising for people with fatty liver disease alongside obesity.
Tirzepatide →
Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.